Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes

Publish date:: July 16, 2019

Key clinical point: Linagliptin seems to be safe even in older people with cardiovascular and renal risk, but it does not improve cardiovascular outcomes.

Major finding: There was no increased risk with linagliptin in the primary composite outcome of cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction, compared with placebo (12.4% vs.12.1%, respectively; HR, 1.02; P = .74).

Study details: Randomized, placebo-controlled trial in more than 6,000 patients with type 2 diabetes.

Disclosures: Boehringer Ingelheim, the maker of linagliptin, funded the study. The presenter disclosed honoraria, speaking fees, and grants from the company. A number of the investigators were employees of the company.

Citation:

REPORTING FROM ADA 2019

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

Substance in tears could be used for diabetes monitoring,

Empagliflozin cut PA pressures in heart failure patients,